With over 80 employees spread across their locations in Birmingham, Alabama and Durham, North Carolina, BioCryst is committed to delivering innovative therapeutics for patients with rare and serious diseases. They have successfully developed ORLADEYO™, an oral medicine approved in the US for the prevention of HAE attacks, and are seeking regulatory approval in Japan and the EU. Additionally, BioCryst has ongoing programs for the treatment of complement-mediated diseases, COVID-19, Marburg virus disease, Yellow Fever, influenza, and fibrodysplasia ossificans progressiva. Their research combines biology, computer modeling, and medicinal chemistry, targeting therapeutic areas such as influenza, hereditary angioedema, filoviruses, and oncology. With expertise in drug discovery, clinical development, and regulatory affairs, BioCryst is dedicated to making a positive impact on patients' lives.